FDA Receives Repros' Submission for Special Protocol Assessment Documentation for Pivotal Studies for Androxal
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced it has received confirmation of delivery of the required documentation for Special Protocol Assessment of its Androxal® Phase 3 pivotal studies to the FDA. Per the Prescription Drug User Fee Act ("PDUFA"), the FDA has 45 calendar days to provide comments back to Repros.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.